Tags

Type your tag names separated by a space and hit enter

The influence of ipratropium bromide in the recovery phase of methacholine induced-bronchospasm.
Eur Rev Med Pharmacol Sci. 2005 Mar-Apr; 9(2):117-23.ER

Abstract

BACKGROUND

The protective effect of Ipratropium Bromide (IB) in the methacholine-induced bronchospasm is well known from some time. The objective of the present study was to assess whether a pretreatment with IB may influence the subsequent phase of methacholine-induced bronchospasm relief.

METHODS

Sixteen patients with bronchial hyper-reactivity (PD20 FEV1 < 200 microg) were randomly assigned to three methacholine challenge tests at a 48 to 72 hours interval apart. In the first test IB was inhaled before the challenge (pre-IB), in the second IB was administered soon after the PD20 FEV1 (post-IB), and in the third no treatment was given (control).

RESULTS

The pre-IB PD20 FEV1 (695 +/- 587.6 microg) was significantly greater (p < 0.0001) than that of post-IB (82.2 +/- 49.18 microg) and of control (73.9 +/- 41.8 microg). The dose response slope (DRS) (decline percentage of FEV1/cumulative methacholine dose), in pre-IB was greatly lower (p < 0.0001) than that in post-IB and in control. During the bronchospasm relief phase, the increase of FEV1 measured after 5, 10, 15, 30 and 60 minutes from the PD20 FEV1 was significantly greater in post-IB (p < 0.05) compared with the other two conditions. Conversely, the recovery slope (RS) (increase percentage of FEV1 at 60 minutes after PD20 FEV1 x cumulative methacholine dose) was significantly more efficient (p < 0.001) in pre-IB than in post-IB and in control.

CONCLUSION

In conclusion, ipratropium bromide confirmed to have a good protective activity against methacholine-induced bronchospasm; the pre-administration of ipratropium bromide showed also a positive effect on the recovery phase.

Authors+Show Affiliations

Dipartimento di Scienze Cardiovascolari e Respiratorie, Università La Sapienza, Rome, Italy. bsposat@tin.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

15945501

Citation

Sposato, B, et al. "The Influence of Ipratropium Bromide in the Recovery Phase of Methacholine Induced-bronchospasm." European Review for Medical and Pharmacological Sciences, vol. 9, no. 2, 2005, pp. 117-23.
Sposato B, Mariotta S, Ricci A, et al. The influence of ipratropium bromide in the recovery phase of methacholine induced-bronchospasm. Eur Rev Med Pharmacol Sci. 2005;9(2):117-23.
Sposato, B., Mariotta, S., Ricci, A., Bruno, P., Terzano, C., & Mannino, F. (2005). The influence of ipratropium bromide in the recovery phase of methacholine induced-bronchospasm. European Review for Medical and Pharmacological Sciences, 9(2), 117-23.
Sposato B, et al. The Influence of Ipratropium Bromide in the Recovery Phase of Methacholine Induced-bronchospasm. Eur Rev Med Pharmacol Sci. 2005 Mar-Apr;9(2):117-23. PubMed PMID: 15945501.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The influence of ipratropium bromide in the recovery phase of methacholine induced-bronchospasm. AU - Sposato,B, AU - Mariotta,S, AU - Ricci,A, AU - Bruno,P, AU - Terzano,C, AU - Mannino,F, PY - 2005/6/11/pubmed PY - 2005/7/6/medline PY - 2005/6/11/entrez SP - 117 EP - 23 JF - European review for medical and pharmacological sciences JO - Eur Rev Med Pharmacol Sci VL - 9 IS - 2 N2 - BACKGROUND: The protective effect of Ipratropium Bromide (IB) in the methacholine-induced bronchospasm is well known from some time. The objective of the present study was to assess whether a pretreatment with IB may influence the subsequent phase of methacholine-induced bronchospasm relief. METHODS: Sixteen patients with bronchial hyper-reactivity (PD20 FEV1 < 200 microg) were randomly assigned to three methacholine challenge tests at a 48 to 72 hours interval apart. In the first test IB was inhaled before the challenge (pre-IB), in the second IB was administered soon after the PD20 FEV1 (post-IB), and in the third no treatment was given (control). RESULTS: The pre-IB PD20 FEV1 (695 +/- 587.6 microg) was significantly greater (p < 0.0001) than that of post-IB (82.2 +/- 49.18 microg) and of control (73.9 +/- 41.8 microg). The dose response slope (DRS) (decline percentage of FEV1/cumulative methacholine dose), in pre-IB was greatly lower (p < 0.0001) than that in post-IB and in control. During the bronchospasm relief phase, the increase of FEV1 measured after 5, 10, 15, 30 and 60 minutes from the PD20 FEV1 was significantly greater in post-IB (p < 0.05) compared with the other two conditions. Conversely, the recovery slope (RS) (increase percentage of FEV1 at 60 minutes after PD20 FEV1 x cumulative methacholine dose) was significantly more efficient (p < 0.001) in pre-IB than in post-IB and in control. CONCLUSION: In conclusion, ipratropium bromide confirmed to have a good protective activity against methacholine-induced bronchospasm; the pre-administration of ipratropium bromide showed also a positive effect on the recovery phase. SN - 1128-3602 UR - https://www.unboundmedicine.com/medline/citation/15945501/The_influence_of_ipratropium_bromide_in_the_recovery_phase_of_methacholine_induced_bronchospasm_ L2 - https://medlineplus.gov/asthma.html DB - PRIME DP - Unbound Medicine ER -